We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain Abiomed (ABMD) Stock for Now
Read MoreHide Full Article
Abiomed, Inc. is well poised for growth in the coming quarters, backed by strength in its Impella product line. A robust first-quarter fiscal 2022 performance, along with solid global foothold, is expected to contribute further. Stiff competition and third-party reimbursement issues persist.
Over the past year, the Zacks Rank #3 (Hold) stock has gained 5.6% compared with 12.9% growth of the industry and 34.5% rise of the S&P 500.
The renowned global provider of medical products designed to assist or replace the pumping function of the failing heart, has a market capitalization of $14.66 billion. The company projects 15% growth for the next five years and expects to maintain its strong performance. It has delivered an earnings surprise of 8.58% for the past four quarters, on average.
Image Source: Zacks Investment Research
Let’s delve deeper.
Strong Q1 Results: Abiomed’s solid first-quarter fiscal 2022 results buoy optimism. The company witnessed strength in its global Impella revenues, which is impressive. In June, Abiomed’s Impella RP with SmartAssist received the FDA’s pre-market approval as safe and effective to treat acute right heart failure for up to 14 days. The company also acquired the remaining interest of preCARDIA, which will help its product portfolio to expand options for upstream heart failure patients acutely decompensating. These developments raise our optimism on the stock. Expansion of both margins bodes well for the stock. A raised full-year revenue outlook buoys our optimism.
Strength in Impella: Abiomed’s flagship product line, Impella, has continued to be a growth driver, which raises our optimism. The company, during its fiscal 2022 first-quarter earnings call in August, confirmed that the Impella 5.5 with SmartAssist has been performing robustly over the past few months. In the quarter, the company’s U.S. Surgical revenues improved significantly as Abiomed expanded the device to 46 more sites. The Impella Connect software has come live at more than 80% of the company’s U.S. sites and approximately 80% of Abiomed’s U.S. patients on support are monitored through the cloud.
In March 2021, Abiomed unveiled the single-access procedure with Impella CP introducer sheaths for the treatment of heart disease, in Europe.
Solid Global Foothold: The Impella support has already been integrated in hospitals throughout Germany and Japan. The company treated patients in Hong Kong, Australia, Singapore, Israel and, most recently, in India. Abiomed has been making impressive progress with its product line in Japan. The company had received the Japanese Pharmaceuticals and Medical Devices Agency’s (“PMDA”) approval from the Ministry of Health, Labour and Welfare (“MHLW”) in March 2019 for its Impella CP heart pump. Abiomed began selling the Impella CP heart pump in Japan in fiscal year 2020.
The company’s Impella 2.5, Impella CP and Impella 5.0 devices have regulatory approval from the MHLW in Japan. Abiomed is also targeting submission of the Impella 5.5 device to the PMDA in Japan in fiscal year 2022.
Downsides
Third-Party Reimbursement: Abiomed depends on third-party reimbursement to its customers for market acceptance of its products. Sales of medical devices largely depend on the reimbursement of patients’ medical expenses by government healthcare programs and private health insurers. Without government reimbursement or third-party insurers’ payments for patient care, the market for Abiomed’s products will be limited.
Stiff Competition: Abiomed faces competition from other companies offering circulatory care products, which is intense and subject to rapid technological change, and evolving industry requirements and standards. It competes with companies that have greater financial, product development, sales and marketing resources, and experience. The company’s ability to compete effectively depends upon its ability to distinguish its company and products from its competitors and their products.
Estimate Trend
Abiomed is witnessing a negative estimate revision trend for 2021. In the past 90 days, the Zacks Consensus Estimate for its earnings has moved 3.1% south to $4.36.
The Zacks Consensus Estimate for the company’s second-quarter fiscal 2022 revenues is pegged at $248.8 million, suggesting an 18.6% improvement from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks from the broader medical space are Henry Schein, Inc. (HSIC - Free Report) , The Cooper Companies, Inc. (COO - Free Report) and Merit Medical Systems, Inc. (MMSI - Free Report) .
Image: Bigstock
Here's Why You Should Retain Abiomed (ABMD) Stock for Now
Abiomed, Inc. is well poised for growth in the coming quarters, backed by strength in its Impella product line. A robust first-quarter fiscal 2022 performance, along with solid global foothold, is expected to contribute further. Stiff competition and third-party reimbursement issues persist.
Over the past year, the Zacks Rank #3 (Hold) stock has gained 5.6% compared with 12.9% growth of the industry and 34.5% rise of the S&P 500.
The renowned global provider of medical products designed to assist or replace the pumping function of the failing heart, has a market capitalization of $14.66 billion. The company projects 15% growth for the next five years and expects to maintain its strong performance. It has delivered an earnings surprise of 8.58% for the past four quarters, on average.
Image Source: Zacks Investment Research
Let’s delve deeper.
Strong Q1 Results: Abiomed’s solid first-quarter fiscal 2022 results buoy optimism. The company witnessed strength in its global Impella revenues, which is impressive. In June, Abiomed’s Impella RP with SmartAssist received the FDA’s pre-market approval as safe and effective to treat acute right heart failure for up to 14 days. The company also acquired the remaining interest of preCARDIA, which will help its product portfolio to expand options for upstream heart failure patients acutely decompensating. These developments raise our optimism on the stock. Expansion of both margins bodes well for the stock. A raised full-year revenue outlook buoys our optimism.
Strength in Impella: Abiomed’s flagship product line, Impella, has continued to be a growth driver, which raises our optimism. The company, during its fiscal 2022 first-quarter earnings call in August, confirmed that the Impella 5.5 with SmartAssist has been performing robustly over the past few months. In the quarter, the company’s U.S. Surgical revenues improved significantly as Abiomed expanded the device to 46 more sites. The Impella Connect software has come live at more than 80% of the company’s U.S. sites and approximately 80% of Abiomed’s U.S. patients on support are monitored through the cloud.
In March 2021, Abiomed unveiled the single-access procedure with Impella CP introducer sheaths for the treatment of heart disease, in Europe.
Solid Global Foothold: The Impella support has already been integrated in hospitals throughout Germany and Japan. The company treated patients in Hong Kong, Australia, Singapore, Israel and, most recently, in India. Abiomed has been making impressive progress with its product line in Japan. The company had received the Japanese Pharmaceuticals and Medical Devices Agency’s (“PMDA”) approval from the Ministry of Health, Labour and Welfare (“MHLW”) in March 2019 for its Impella CP heart pump. Abiomed began selling the Impella CP heart pump in Japan in fiscal year 2020.
The company’s Impella 2.5, Impella CP and Impella 5.0 devices have regulatory approval from the MHLW in Japan. Abiomed is also targeting submission of the Impella 5.5 device to the PMDA in Japan in fiscal year 2022.
Downsides
Third-Party Reimbursement: Abiomed depends on third-party reimbursement to its customers for market acceptance of its products. Sales of medical devices largely depend on the reimbursement of patients’ medical expenses by government healthcare programs and private health insurers. Without government reimbursement or third-party insurers’ payments for patient care, the market for Abiomed’s products will be limited.
Stiff Competition: Abiomed faces competition from other companies offering circulatory care products, which is intense and subject to rapid technological change, and evolving industry requirements and standards. It competes with companies that have greater financial, product development, sales and marketing resources, and experience. The company’s ability to compete effectively depends upon its ability to distinguish its company and products from its competitors and their products.
Estimate Trend
Abiomed is witnessing a negative estimate revision trend for 2021. In the past 90 days, the Zacks Consensus Estimate for its earnings has moved 3.1% south to $4.36.
The Zacks Consensus Estimate for the company’s second-quarter fiscal 2022 revenues is pegged at $248.8 million, suggesting an 18.6% improvement from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks from the broader medical space are Henry Schein, Inc. (HSIC - Free Report) , The Cooper Companies, Inc. (COO - Free Report) and Merit Medical Systems, Inc. (MMSI - Free Report) .
Henry Schein’s long-term earnings growth rate is estimated at 13.9%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cooper Companies’ long-term earnings growth rate is estimated at 10%. It currently carries a Zacks Rank #2.
Merit Medical’s long-term earnings growth rate is estimated at 13.6%. It currently has a Zacks Rank #2.